StockData
Regencell Bioscience Holdings Ltd logo

Regencell Bioscience Holdings Ltd (RGC) stock

RGCNasdaqMedicinal Chemicals & Botanical Products
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 7, 2026Score 5/30
$4.55−0.17 (-3.60%)

Close on Nov 17, 2026Market cap $2.26BP/E –Yield –

Regencell Bioscience r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2026 it was $1.30M, up 37.0% from the year before. The highest annual figure on record is $2.51M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Jun 30, 2026$1.30M+37.0%
FY2025Jun 30, 2025$948.29K-11.1%
FY2024Jun 30, 2024$1.07M-32.6%
FY2023Jun 30, 2023$1.58M-37.0%
FY2022Jun 30, 2022$2.51M+473.1%
FY2021Jun 30, 2021$438.32K+13.5%
FY2020Jun 30, 2020$386.23K+69.2%
FY2019Jun 30, 2019$228.22K–

More Regencell Bioscience figures

See a number that looks wrong?